Naren Ramakrishna

Dr. Naren Ramakrishna

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SGSharon H. Giordano
Sharon H. Giordano
MFMaria Alice B. Franzoi
Maria Alice B. Franzoi
STSarah Temin
Sarah Temin
CACarey K. Anders
Carey K. Anders
SCSarat Chandarlapaty
Sarat Chandarlapaty
NDNancy E. Davidson
Nancy E. Davidson
PURPOSE: To update evidence-based guideline recommendations to practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2)–positive advanced breast cancer. METHODS: An Expert Panel conducted a targeted systematic literature review (for both systemic treatment and CNS metastases) and identified 545 articles. Outcomes of interest included efficacy and safety. RESULTS: Of the 545 publications identified and reviewed, 14 were identified to form the evidentiary basis for the guideline recommendations. RECOMMENDATIONS: HER2-targeted therapy is recommended for patients with HER2-positive advanced breast cancer, except for those with clinical congestive heart failure or significantly compromised left ventricular ejection fraction, who should be evaluated on a case-by-case basis. Trastuzumab, pertuzumab, and taxane for first-line treatment and trastuzumab deruxtecan for second-line treatment are recommended. In the third-line setting, clinicians should offer other HER2-targeted therapy combinations. There is a lack of head-to-head trials; therefore, there is insufficient evidence to recommend one regimen over another. The patient and the clinician should discuss differences in treatment schedule, route, toxicities, etc during the decision-making process. Options include regimens with tucatinib, trastuzumab emtansine, trastuzumab deruxtecan (if either not previously administered), neratinib, lapatinib, chemotherapy, margetuximab, hormonal therapy, and abemaciclib plus trastuzumab plus fulvestrant, and may offer pertuzumab if the patient has not previously received it. Optimal duration of chemotherapy is at least 4-6 months or until maximum response, depending on toxicity and in the absence of progression. HER2-targeted therapy can continue until time of progression or unacceptable toxicities. For patients with HER2-positive and estrogen receptor–positive or progesterone receptor–positive breast cancer, clinicians may recommend either standard first-line therapy or, for selected patients, endocrine therapy plus HER2-targeted therapy or endocrine therapy alone. Additional information is available at www.asco.org/breast-cancer-guidelines .

10 August 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NRNaren Ramakrishna
Naren Ramakrishna
CACarey K. Anders
Carey K. Anders
NLNancy U.T. Lin
Nancy U.T. Lin
AMAki Morikawa
Aki Morikawa
STSarah Temin
Sarah Temin
SGSharon H. Giordano
Sharon H. Giordano
PURPOSE: To provide updated evidence- and consensus-based guideline recommendations to practicing oncologists and others on the management of brain metastases for patients with human epidermal growth factor receptor 2 (HER2)–positive advanced breast cancer up to 2021. METHODS: An Expert Panel conducted a targeted systematic literature review (for both systemic therapy for non-CNS metastases and for CNS metastases of HER2+ guideline updates) that identified 545 articles. Outcomes of interest included overall survival, progression-free survival, and adverse events. RESULTS: Of the 545 publications identified and reviewed, six on systemic therapy were identified to form the evidentiary basis for the systemic therapy for CNS metastases guideline recommendations. RECOMMENDATIONS: Patients with brain metastases should receive appropriate local therapy and systemic therapy, if indicated. Local therapies include surgery, whole-brain radiotherapy, and stereotactic radiosurgery. Memantine and hippocampal avoidance should be added to whole-brain radiotherapy when possible. Treatments depend on factors such as patient prognosis, presence of symptoms, resectability, number and size of metastases, prior therapy, and whether metastases are diffuse. Other options include systemic therapy, best supportive care, enrollment onto a clinical trial, and/or palliative care. There are insufficient data to recommend for or against performing routine magnetic resonance imaging to screen for brain metastases; clinicians should have a low threshold for magnetic resonance imaging of the brain because of the high incidence of brain metastases among patients with HER2-positive advanced breast cancer. Additional information is available at www.asco.org/breast-cancer-guidelines .

7 November 2013 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
NLNancy U.T. Lin
Nancy U.T. Lin
RFRachel A. Freedman
Rachel A. Freedman
NRNaren Ramakrishna
Naren Ramakrishna
JYJerry Younger
Jerry Younger
ASAnna Maria Storniolo
Anna Maria Storniolo
EWEric P. Winer
Eric P. Winer

1 September 2020 in Practical Radiation Oncology
Verified
Journal Article
Closed access
GGGordon Glober
Gordon Glober
AKAlex Kubli
Alex Kubli
JKJerrold E Kielbasa
Jerrold E Kielbasa
BCBhavin Chauhan
Bhavin Chauhan
DBDouglas Burch
Douglas Burch
PKPatrick Kelly
Patrick Kelly

8 November 2012 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
MKMarie-Adele S Kress
Marie-Adele S Kress
NRNaren Ramakrishna
Naren Ramakrishna
SMSolomon B Makgoeng
Solomon B Makgoeng
KUKeith Unger
Keith Unger
APArnold L Potosky
Arnold L Potosky
Limited data guide radiotherapy choices for patients with brain metastases. This survey aimed to identify patient, physician, and practice setting variables associated with reported preferences for different treatment techniques.

1 November 2022 in JCO Oncology Practice
Verified
Journal Article
Closed access
NRNaren Ramakrishna
Naren Ramakrishna
CACarey K. Anders
Carey K. Anders
STSarah Temin
Sarah Temin